Immunosuppression in chronic autoimmune neurological disorders during the COVID-19 pandemic

OBJECTIVE: To study the risk of acquiring Corona Virus Disease 2019 (COVID-19) and its outcomes in patients on immunosuppressive therapy (IST) for chronic autoimmune neuromuscular disorders (aNMD) and multiple sclerosis (MS). METHODS: We used TriNetX, a global health collaborative clinical research...

Descripción completa

Detalles Bibliográficos
Autores principales: Kovvuru, Sukanthi, Nalleballe, Krishna, Onteddu, Sanjeeva Reddy, Sharma, Rohan, Jasti, Madhu, Kapoor, Nidhi, Veerapaneni, Karthika, Yadala, Sisira, Dandu, Vasuki, Archer, Robert, Nowak, Richard J., Roy, Bhaskar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837234/
https://www.ncbi.nlm.nih.gov/pubmed/33256952
http://dx.doi.org/10.1016/j.jns.2020.117230

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837234/
https://www.ncbi.nlm.nih.gov/pubmed/33256952
http://dx.doi.org/10.1016/j.jns.2020.117230

Ejemplares similares